ZGN 1061

Drug Profile

ZGN 1061

Alternative Names: ZGN-1061; ZGN1601

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Zafgen
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 09 Mar 2017 Zafgen plans a phase II trial for Type 2 diabetes mellitus and Obesity in Australia
  • 01 Mar 2017 Zafgen has a patent co-operation treaty patent pending for ZGN 1601
  • 01 Mar 2017 Zafgen has patent protection for MetAP2 inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top